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Abstract
REV3 is the catalytic subunit of DNA translesion synthesis polymerase ζ. Inhibition of REV3 expression increases
the sensitivity of human cells to a variety of DNA-damaging agents and reduces the formation of resistant cells.
Surprisingly, we found that short hairpin RNA–mediated depletion of REV3 per se suppresses colony formation of
lung (A549, Calu-3), breast (MCF-7, MDA-MB-231), mesothelioma (IL45 and ZL55), and colon (HCT116 +/−p53)
tumor cell lines, whereas control cell lines (AD293, LP9-hTERT) and the normal mesothelial primary culture
(SDM104) are less affected. Inhibition of REV3 expression in cancer cells leads to an accumulation of persistent
DNA damage as indicated by an increase in phospho-ATM, 53BP1, and phospho-H2AX foci formation, subse-
quently leading to the activation of the ATM-dependent DNA damage response cascade. REV3 depletion in
p53-proficient cancer cell lines results in a G1 arrest and induction of senescence as indicated by the accumulation
of p21 and an increase in senescence-associated β-galactosidase activity. In contrast, inhibition of REV3 expres-
sion in p53-deficient cells results in growth inhibition and a G2/M arrest. A small fraction of the p53-deficient can-
cer cells can overcome the G2/M arrest, which results in mitotic slippage and aneuploidy. Our findings reveal that
REV3 depletion per se suppresses growth of cancer cell lines from different origin, whereas control cell lines and a
mesothelial primary culture were less affected. Thus, our findings indicate that depletion of REV3 not only can
amend cisplatin-based cancer therapy but also can be applied for susceptible cancers as a potential monotherapy.
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Introduction
Screening in Saccharomyces cerevisiae for mutants defective in UV-
induced mutagenesis revealed the so-called reversionless phenotype
(REV), which is characterized by a diminished frequency of muta-
tions reverting a specific marker gene deficiency [1]. Two genes that
confer this phenotype when absent are Rev3 and Rev7, the catalytic
and the structural subunits of the DNA translesion synthesis (TLS)
polymerase ζ (Pol ζ), respectively [2,3]. The mammalian REV3L
gene (hereafter REV3) encodes a ∼350-kDa protein (REV3) consist-
ing of a large C-terminal DNA polymerase subunit, which misses the
characteristic proofreading activity present in other B-family DNA
polymerases (reviewed in Waters et al. [4]). REV3 interacts through
a specific binding domain with REV7, but no additional protein-
protein interaction sites were identified. Deletion of REV3 is embry-
onically lethal around midgestation [5–8], whereas overexpression of
REV3 leads to increased spontaneous mutation rates [9], confirming
that REV3 expression has to be tightly regulated to maintain genomic
integrity. Conversely, one study found that REV3 expression was
downregulated in colon carcinomas compared with that in adjacent
normal tissue [10], whereas another study found that REV3 expression
was elevated in human glioma tissues resected before therapy com-
pared with that in normal brain tissues [11].
Abbreviations: TLS, DNA translesion synthesis; Pol ζ, DNA translesion synthesis poly-
merase ζ; REV3, the mammalian REV3L gene; MEF, mouse embryonic fibroblast; DDR,
DNA damage response; DSBs, DNA double-strand breaks; ATM, ataxia-telangiectasia
mutated; γH2AX, phosphorylated H2AX; P-Chk2, phosphorylated Chk2; AN, aneu-
ploid nondividing; AD, aneuploid dividing
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Pol ζ belongs to the functional group of TLS DNA polymerases,
which are characterized by a less-stringent active site and a lower pro-
cessivity compared with the high-fidelity replicative DNA polymerases
(reviewed in Waters et al. [4]). TLS polymerases contribute to the
maintenance of the genomic integrity by allowing DNA replication
to continue in the presence of DNA adducts, which otherwise could
lead to DNA replication fork breakdown and subsequent gross chro-
mosomal instability. Pol ζ is the major extender from mismatches
formed when incorrect nucleotides are inserted opposite DNA ad-
ducts, thereby contributing to mutation formation on the nucleotide
level. Recently, it was shown that REV3 is involved not only in DNA
damage tolerance but also in DNA repair mechanisms, for example, in-
terstrand cross-link repair [12–14], homologous recombination [15],
and nonhomologous end-joining as indicated by the deficiency of
REV3-deleted B cells in class switching of immunoglobulin genes [16].
The unique function of REV3 is highlighted by the fact that theREV3
depletion increases sensitivity and decreases mutagenesis induced by UV
light, cisplatin, and other mutagens in human and mouse fibroblasts
[15,17,18]. In addition, depletion of REV3 sensitizes mouse B-cell lym-
phomas and lung adenocarcinomas to cisplatin [19,20]. Although dis-
ruption of mouse REV3 leads to embryonic lethality, it is possible to
generate REV3-deleted mouse embryonic fibroblasts (MEFs) in a p53-
deficient background [21]. Spontaneous chromosomal instability was
observed inREV3-deletedMEFs andREV3-deleted cell lines [16,22,23].
DNA damage induction results in the activation of an evolution-
arily conserved signal cascade known as DNA damage response
(DDR) (reviewed in d’Adda di Fagagna [24]). Induction of DNA
double-strand breaks (DSBs) results in recruitment and activation
of ataxia-telangiectasia mutated (ATM). Activated ATM phosphory-
lates the histone variant H2AX at serine 139 (γH2AX) near DNA
DSBs, subsequently leading to an accumulation of DDR proteins
at DSBs, which can be visualized by immunofluorescence microscopy
as distinct foci. Once ATM activation reaches a certain threshold,
checkpoint kinase Chk2 is phosphorylated, resulting in the accumula-
tion of p53, leading to the accumulation of the cyclin-dependent kinase
inhibitor p21. Prolonged activation of p21 after DNA damage is asso-
ciated with a terminal proliferation arrest, i.e., senescence.
While investigating how inhibition of REV3 expression affects
cisplatin-induced mutagenesis, we observed that depletion of REV3
per se reduces cancer cell growth, whereas growth of control cells is
less affected. Suppression of REV3 expression in cancer cells leads to
the accumulation of persistent DNA damage independent of the p53
status. In p53-proficient cancer cells, inhibition of REV3 expression
results in the activation of the ATM-dependent DDR cascade, lead-
ing to senescence induction. In p53-deficient cancer cells, depletion
of REV3 results in a G2/M arrest and increases the fraction of aneu-
ploid cells. In contrast, inhibition of REV3 expression in control cell
lines and a mesothelial primary culture neither reduces colony forma-
tion nor activates the DDR cascade.
Materials and Methods
Cell Lines and Culture
All cell lines used in this study were authenticated by DNA finger-
printing (Microsynth, Balgach, Switzerland). SDM104 was maintained
as described previously [25]. All other cell lines weremaintained in high-
glucose Dulbecco modified Eagle medium (DMEM; Sigma-Aldrich,
St Louis, MO) supplemented with 2 mM L-glutamine, 1 mM sodium
pyruvate, 10% fetal calf serum, and 1% (wt/vol) penicillin/streptomycin.
All cells were grown at 37°C in a humidified atmosphere containing
5% CO2. Additional details can be found in Supplemental Materials
and Methods.
Vector Production and Transduction
Replication-deficient lentiviral particles were produced, titrated,
and used for transduction as described previously [26,27]. Additional
details can be found in Supplemental Materials and Methods.
Plasmid Transfection
Cells were transfected using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions with
pSuperior.puro containing either scrambled control short hairpin
RNA (shSCR) or three distinct short hairpin RNA (shRNA) se-
quences targeting the REV3 messenger RNA (shREV3). Additional
details can be found in Supplemental Materials and Methods.
Colony Formation Assay
Crystal violet staining was performed after colonies were visible by
eye and, the number of colonies was determined by eye, applying the
same threshold for colony size to all transduced cell lines. The num-
ber of colonies obtained by mock treatment was set to 100%.
Quantitative Real-time Polymerase Chain Reaction
RNA from samples was isolated using RNeasy Mini kit (Qiagen,
Germantown, MD), and reverse transcription was performed on
300 ng of RNA (QuantiTect Reverse Transcription Protocol; Qiagen).
The quantitative expression of REV3 mRNA was measured by SYBR
Green polymerase chain reaction (PCR) assay (PE Applied Biosystems,
Foster City, CA) on a Prism 5700 detection system (SDS; PE Applied
Biosystems). Additional details can be found in Supplemental Mate-
rials and Methods.
Immunofluorescence Microscopy
Immunofluorescence microscopy was essentially performed as
described [28]. Details can be found in Supplemental Materials
and Methods.
Flow Cytometry
Detection of bromodeoxyuridine (BrdU) incorporation in DNA-
synthesizing cells was carried out using the anti-BrdU antibody (no.
555627; BD Biosciences, San Jose, CA) according to the manufac-
turer’s instructions. Additional details can be found in Supplemental
Materials and Methods.
Senescence-Associated β-Galactosidase Assay
The expression of senescence-associated (SA) β-galactosidase was
determined by SA-β-galactosidase staining as described [29].
Western Analysis
Protein extracts (30 μg) were separated by 4% to 20% SDS-PAGE
and transferred onto polyvinylidene fluoride membranes. Immuno-
blot analysis was performed as described [30]. Details can be found
in Supplemental Materials and Methods.
Enzyme-Linked Immunosorbent Assay
Cells were washed three times with phosphate-buffered saline (PBS)
and serum-free DMEMwas added for 24 hours. Conditionedmedium
was filtered, and cell number was determined in every experiment by
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hemocytometer. Enzyme-linked immunosorbent assay (ELISA) was
performed using human interleukin 6 (IL-6) Quantikine ELISA Kit
(no. D6050; R&D Systems, Minneapolis, MN). Data were normal-
ized to the cell number and reported as fold difference compared with
mock-treated control.
Statistical Analysis
P values were calculated using the two-tailed Student’s t test; *P <
.05 and **P < .01.
Results
Depletion of REV3 Per Se Suppresses Colony Formation
of Cancer Cells
To study the effect of REV3 depletion on cisplatin-induced muta-
genesis, we established a lentiviral-based system, which allowed us to
significantly inhibit REV3 expression in all cell lines and the primary
culture used in this study (Figure W1, A and B). Inhibition of REV3
expression did not significantly reduce colony formation of the con-
trol cell line AD293 (99% remaining colonies compared with mock-
treated control), the primary mesothelial culture SDM104 (81%),
and the hTERT-immortalized derivative of the mesothelial primary
culture LP9 (LP9-hTERT, 98%; Figures 1A and W2A). Surprisingly,
REV3 depletion per se significantly suppressed colony formation of
the p53-proficient adenocarcinoma cell line A549 (30%), the p53-
deficient adenocarcinoma cell line Calu-3 (57%), the p53-deficient
breast cancer cell line MDA-MB-231 (47%), the p53-proficient breast
cancer cell line MCF-7 (32%), the human mesothelioma cell line
ZL55 (27%), and the rat mesothelioma cell line IL45 (4%) compared
with the mock-treated control (Figures 1A and W2A).
In the isogenic p53-proficient and -deficient HCT116 colorectal
carcinoma cell lines, there was no significant difference in the reduc-
tion of REV3 expression levels after transduction with a multiplic-
ity of infection (MOI) of 170, as used for the cell lines described
previously, or an MOI of 800 (Figure W1B). However, only the
high-titer transduction significantly suppressed colony formation of
p53-proficient (49%) and -deficient HCT116 (54%) compared with
the mock control (Figures 1B and W2B). REV3 depletion by high-
titer transduction did not significantly reduce colony formation of
the control cell line AD293 (74%) compared with the mock control
(Figures 1B and W2B).
Inhibition of REV3 expression by transduction with three plas-
mids, one encoding the same small interfering RNA (siRNA) as
the lentiviral-based particles plus two plasmids encoding siRNA tar-
geting alternative sites of the REV3 mRNA (named REV3-5 and
REV3-6), significantly reduced colony formation in the mesothe-
lioma cell line IL45, whereas the control cell line AD293 was not
affected (Figure W3). Therefore, we conclude that the observed re-
duction in colony formation is due to the inhibition of REV3 expres-
sion and not due to an unspecific off-target effect of the REV3-4
siRNA. Thus, REV3 depletion per se significantly suppresses colony
formation in cancer cell lines, whereas colony formation of control
cell lines and a primary mesothelial culture is less affected.
Cancer Cells Accumulate Persistent DNA DSBs after
REV3 Depletion
53BP1 and γH2AX foci formation is regarded as a maker for
DSBs [28], and a recent study showed that their numbers were
increased after persistent DNA damage induction [31]. Seven days
after transduction, REV3 depletion in A549 cells increased the
Figure 1. Inhibition of REV3 expression specifically reduces colony formation of cancer cell lines. Cells were mock treated or transduced
with lentiviral-based particles containing either shSCR or shREV3. (A and B) Cells were stained by crystal violet, and total colonies were
counted after 2 to 4 weeks. Colonies were counted from at least three independent experiments for all cell lines. Colony numbers of
mock-treated cells were set as 100%. *P < .05. **P < .01. Shown are means ± standard deviation (SD).
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average number of P-ATM and γH2AX foci per cell by a factor
of 3.8 and 2.3, respectively, compared with the mock control
(Figure 2A). Inhibition of REV3 expression increased the fraction
of A549 cells containing more than two 53BP1 foci to 34% com-
pared with mock (2%) and scrambled (16%) control (Figure 2A).
Similarly, REV3 depletion in MCF-7 breast cancer cells increased
the average number of γH2AX and 53BP1 foci per cell by a factor
of 3.2 and 2.5, respectively, compared with the mock control
(Figure W4). P-ATM foci formation was also elevated in both
p53-proficient and -deficient HCT116 cells after REV3 depletion
by a factor of 2.3 and 2.5, respectively, compared with the scrambled
control (Figure 2B). In contrast, inhibition of REV3 expression in the
control cell line AD293 did not significantly increase P-ATM,
53BP1, or γH2AX foci formation compared with the scrambled
control (Figure 2A).
DSBs, which are not repaired either due to complex DNA mod-
ifications or to deficiencies in molecular mechanisms result in the
formation of persistent DSBs (reviewed in d’Adda di Fagagna [24]).
P-ATM foci at persistent DSBs are significantly larger than the initial
foci detectable immediately after damage initiation [32]. Microscopic
analysis revealed that the DDR foci induced in REV3-depleted cells
7 days after transduction were larger compared with the background
DDR foci present in the mock controls (Figure 2A).
Gross chromosomal instability indicated by an elevated number of
micronuclei were observed in MEFs with REV3 deletion [21]. Sim-
ilarly, the number of micronuclei increased in A549 cells by a factor
of 9 after inhibition of REV3 expression compared with the mock
control (Figure 2C ). Micronuclei formation was not significantly
elevated after inhibition of REV3 expression in AD293 cells (Fig-
ure 2C ). Thus, inhibition of REV3 expression induces the formation
of persistent DSBs and accumulation of gross chromosomal instabil-
ity in cancer cell lines, whereas the control cell line AD293 is signif-
icantly less affected (P < .05 for γH2AX, P-ATM, and 53BP1 foci
and micronuclei per cell for both A549 and MCF-7 vs AD293;
numbers of P-ATM foci per cell were not determined in MCF-7
cells). In addition, our results indicate that persistent DDR foci for-
mation after REV3 depletion is not dependent on the p53 status.
Inhibition of REV3 Expression Suppresses Proliferation
of Cancer Cells
Because persistent DNA adducts block DNA replication and acti-
vate the DDR pathway, we investigated whether inhibition of REV3
expression results in reduced cellular proliferation. Labeling of newly
synthesized DNA with BrdU is an established method for the assess-
ment of cellular proliferation (reviewed in Quinn and Wright [33]).
Figure 2. REV3 depletion induces persistent DNA damage and genomic instability specifically in cancer cells. Cells were mock treated or
transduced with lentiviral-based particles containing either shSCR or shREV3 and analyzed after 1 week. (A) Cells were stained for
P-ATM, γH2AX, or BrdU (all green) and 53BP1 (red) and quantified by immunofluorescence microscopy. Cells containing more than
two 53BP1 foci per cell were considered as 53BP1 positive. (B) Cells were stained for P-ATM, and foci per cell were quantified by
immunofluorescence microscopy. (C) Cells were stained for γH2AX (green) and nuclear DNA was labeled with DAPI (blue). Micronuclei
formation was identified by immunofluorescence microscopy–based analysis of DAPI staining. At least three independent experiments
were analyzed. *P < .05. **P < .01. Shown are means ± SD.
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Quantitative analysis of BrdU incorporation revealed that cellular
proliferation of A549 cells was reduced by REV3 depletion to 21%
compared with 37% and 38% in mock and scrambled controls, re-
spectively (Figure 3, see also Figure 2A). Inhibition of REV3 expres-
sion reduced the proliferation of p53-proficient HCT116 cells to
25% and that of p53-deficient HCT116 cells, to a lesser extent, to
33% compared with 41% and 45% in their corresponding scram-
bled controls, respectively (Figure 3). Similarly, REV3 depletion also
reduced the proliferation of MCF-7 breast cancer cells to 9.2% com-
pared with 17% and 19% in mock and scrambled controls, respec-
tively (Figure W4). In contrast, the percentage of replicating cells in
the control cell line AD293 and the primary cell culture SDM104
was not diminished by the inhibition of REV3 expression (Figure 3).
Thus, REV3 depletion suppresses cellular proliferation of the analyzed
cancer cells, whereas proliferation of control cells is not affected.
REV3 Depletion Activates the DNA Damage Response
Pathway in Cancer Cells
We investigated whether the observed accumulation of persistent
DSBs in cancer cells results in the activation of the canonical ATM-
kinase–mediated DDR pathway, which is induced by DSBs (re-
viewed in d’Adda di Fagagna [24]). As described here, the number
of phospho-ATM foci per cell increased after the inhibition of REV3
expression compared with mock and scrambled controls in A549 and
p53-proficient and -deficient HCT116 cells, whereas no significant
increase occurred in AD293 control cells (Figure 2, A and B). In
A549 cells, REV3 depletion resulted in increased phosphorylation
of the checkpoint kinase Chk2 (P-Chk2) and the accumulation of
p53 and the senescence mediator p21 (Figure 4A), which was also
observed in MCF-7 breast cancer cells but not in the normal meso-
thelial primary culture SDM104 (Figure W5). In p53-proficient
HCT116 cancer cells, inhibition of REV3 expression also resulted
in an accumulation of p21, which was absent in the p53-deficient
isogenic cell line (Figure 4A). Thus, in the analyzed p53-proficient
cancer cells, inhibition of REV3 expression results in the activation
of the canonical ATM-dependent DDR pathway.
REV3 Depletion Induces a G1 Arrest in p53-Proficient
Cancer Cells
We tested whether the activation of the DDR pathway and the
reduction in BrdU incorporation due to REV3 depletion change
the cell cycle distribution of cancer cells. Depletion of the S phase
after REV3 depletion, as mentioned here, was accompanied by a sig-
nificant increase in the fraction of A549 cells in the G1 phase of the
Figure 3. REV3 depletion changes cell cycle distribution of cancer cell lines. Cells were mock treated or transduced with lentiviral-based
particles containing either shSCR or shREV3 and/or lentiviral-based particles containing shP53. After 1 week, cell cycle distribution was
measured by BrdU/propidium iodide staining and subsequent FACS analysis. The averages of three independent experiments are given
for A549, A549 shP53, p53-proficient HCT116, and p53-deficient HCT116 cells, whereas representative experiments are shown for
SDM104 and AD293 cells. *P < .05. **P < .01. Shown are means ± SD.
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cell cycle to 62% compared with 53% and 51% in the mock and
scrambled controls, respectively (Figure 3). Similarly, the fraction
of p53-proficient HCT116 cells in the G1 phase increased to 38%
after inhibition of REV3 expression compared with 26% in scrambled
control, respectively (Figure 3). In the control cell line AD293 and
the primary cell culture SDM104, neither the fraction of cells in the
S phase was decreased nor was the fraction of cells in the G1 phase
increased after inhibition of REV3 expression compared with mock
and scrambled controls (Figure 3). A small but significant increase
in the fraction of cells in the G2 phase was observed in p53-proficient
HCT116 cells after REV3 depletion (23%) compared with mock
(17%) and scrambled controls (19%). In addition, protein levels of
cyclin E, which accumulate during the G1 phase and are required
for the transition from the G1 phase to the S phase, increased after
inhibition of REV3 expression in p53-proficient but not in p53-
deficient HCT116 cancer cells (Figure 4A). Thus, inhibition of
REV3 expression in the investigated p53-proficient cancer cell lines
induces a G1 arrest, respectively, S-phase depletion, whereas the cell
cycle distribution of the investigated control cell line and the primary
mesothelial culture was not affected.
Inhibition of REV3 Expression Induces Senescence in
p53-Proficient Cancer Cells
Although inhibition of REV3 expression slightly increased the frac-
tion of sub-G1 cells in p53-proficient A549 and HCT116 cells, no
significant induction of apoptosis as indicated by an increased fraction
of sub-G1 cells (Figure 3) or poly(ADP-ribose) polymerase (PARP)
cleavage (Figure 4A) was observed in the remaining control and cancer
cell lines tested in this study.
Because senescence can be induced by persistent DNA damage
[31], we investigated whether cells are senescent after REV3 deple-
tion. Induction of senescence cannot be identified by a single marker
but is associated with a variety of distinct cellular and molecular
changes (reviewed in Collado and Serrano [34]). Microscopic analysis
after crystal violet staining revealed that the morphology of control
AD293 cells was not changed 7 days after inhibition of REV3 ex-
pression compared with mock and scrambled controls (Figure W6).
In the p53-proficient cancer cell lines included in this study, most
colonies were smaller after REV3 depletion, and the cells of these
colonies displayed morphologic changes that are associated with se-
nescence, namely, increased cell size and flattened shape, whereas
cell morphology was not affected in mock and scrambled controls
(Figure W6). SA-β-galactosidase staining revealed increased SA-β-
galactosidase activity in IL45, A549, and HCT116 p53-proficient
cells after inhibition of REV3 expression (Figure W6 and Table 1).
No increase in SA-β-galactosidase staining after inhibition of REV3
expression was detectable in the control cells AD293 or in the p53-
deficient MDA-MB-231 and HCT116 cancer cell lines. As men-
tioned previously, G1 arrest, respectively, S-phase depletion and p21
accumulation were observed in A549 and p53-proficient HCT116
cells after REV3 depletion (Figures 3 and 4A).
An increase in persistent DNA damage indicated by residual 53BP1/
γH2AX foci is associated in human foreskin fibroblasts with a senescence-
associated secretory phenotype including cytokine secretion such as
IL-6 [31]. Twelve days after transduction, IL-6 secretion was increased
in A549 cell after inhibition of REV3 expression compared with mock
and scrambled controls (Figure 4B). In contrast, REV3 depletion in p53-
deficient HCT116 cells did not result in a G1 accumulation nor did
it increase p21 levels or increase SA-β-galactosidase staining (Figures 3,
4A, and W6 and Table 1). Similarly, G1 accumulation and SA-β-
galactosidase staining were abolished in A549 by p53 inhibition (Fig-
ure 3 and Table 1). Thus, among the analyzed cancer cell lines, REV3
depletion per se induces senescence in p53-proficient cancer cells only.
REV3 Depletion Induces a G2 /M Arrest and Aneuploidy in
p53-Deficient Cancer Cells
No G1 arrest was detectable in p53-deficient HCT116 cell after
inhibition of REV3 expression (Figure 3). Instead, REV3 depletion
Figure 4. REV3 depletion induces DDR pathway in cancer cells.
Cells were cisplatin or mock treated or transduced with lentiviral-
based particles containing either shSCR or shREV3. (A) After 1 week,
whole-cell lysates were analyzed by Western analysis. (B) After
24 hours, IL-6 secretion in serum-free DMEM was assessed by
ELISA, normalized to the cell number and reported as fold increase
compared with mock-treated control. The averages of at least three
independent experiments are given. Shown are means ± SD.
Table 1. Induction of Senescence after REV3 Inhibition Is Dependent on p53 Level.
p53 Cell Line Mock shSCR shREV3 t test shSCR/shREV3
+ IL45 2.3 ± 0.7 2.8 ± 1.0 44.2 ± 4.0 *
+ A549 5.8 ± 0.7 6.0 ± 1.4 16.1 ± 2.3 *
− A549 shP53 1.0 ± 0.3 0.9 ± 0.3 0.9 ± 0.3 NS
− MDA-MB-231 0 0 0 N/A
+ AD293 (normal) 0 0 0 N/A
Three independent experiments were analyzed for all cell lines. Shown are means (%) of senescent
cells ± SEM.
N/A indicates not applicable; NS, not significant.
*P < .01%.
966 REV3 Depletion Per Se Reduces Cancer Cell Growth Knobel et al. Neoplasia Vol. 13, No. 10, 2011
in the p53-deficient HCT116 cell line significantly increased the
fraction of cells in the G2/M phase to 26% compared with 17%
and 18% in the mock and scrambled controls, respectively (Figure 3).
In addition, inhibition of REV3 expression also increased the frac-
tion of aneuploid cells, which did not incorporate BrdU (AN, aneu-
ploid nondividing) to 7% compared with 3% and 4% in the mock
and scrambled controls (Figure 3). The fraction of aneuploid cells,
which were still incorporating BrdU (AD, aneuploid dividing), was
not increased after REV3 depletion in p53-deficient HCT116 cells
compared with mock and scrambled controls (Figure 3). Thus, inhi-
bition of REV3 expression in the investigated p53-deficient cancer
cells results in the accumulation of G2/M arrested and AN cells.
In an effort to provide proof-of-principle, we inhibited p53 expres-
sion in p53-proficient A549 cancer cells (Figure W1C ). Inhibition of
p53 expression in A549 cells resulted in a significant increase of the
cells in the G2 phase (22%) and in aneuploidy (total 14%) compared
with p53-proficient A549 cells (7.5% and 1.8%, respectively; Fig-
ure 3), which is in agreement with the dominant role of p53 in
the induction of the G1 arrest [35]. The dominant role of p53 in
protection from aneuploidy is highlighted by the finding that addi-
tional inhibition of REV3 expression in combination with p53 inhi-
bition did not further increase aneuploidy in A549 cancer cells.
Discussion
During our study on the involvement of REV3 in chemotherapy re-
sponse, we found that lentiviral-based inhibition of REV3 expression
was as efficient in the analyzed cancer cell lines as in the primary meso-
thelial culture and the control cell lines, but surprisingly, colony forma-
tion was reduced in the cancer cell lines only. Therefore, we conclude
that reduction in colony formation does not simply mirror the degree
of REV3 expression inhibition relative to the scrambled control.
We found that colony formation was not significantly reduced in
the control cell lines AD293 and LP9-hTERT and the primary meso-
thelial culture SDM104 and after inhibition of REV3 expression.
This is consistent with previous studies where no deficiency in cell
growth/survival was mentioned after antisense-based inhibition of
REV3 expression in human nontumor cell lines [17,36]. In contrast,
it was shown by different groups that REV3 knockout reduced cell
growth of MEFs [21,37]. Thus, additional studies will be necessary
to clarify how normal cells adapt their DDR to tolerate the loss of
REV3 function. At this point, it is worth mentioning that investiga-
tions of cancer-specific pathways are usually performed using so-
called normal cells as control. However, normal cells have a limited
life span [38], which also applies to the primary mesothelial culture
SDM104. In contrast, the control cell lines AD293 and LP9-hTERT
are virally transformed or immortalized by transfection with human
telomerase, respectively, to achieve unlimited proliferation in cell cul-
ture. Thus, AD293 and LP9-hTERT might not fully represent nor-
mal cells, although they have been widely used as normal controls
[39,40] and their response to REV3 depletion was consistent with
the reaction of the primary mesothelial cell culture SDM104.
Studies have shown controversial results on the effect of REV3
depletion on cancer cell growth. On one hand, no deficiency in
cell growth/survival was mentioned after si/shRNA–based inhibi-
tion of REV3 expression in HCT116, U2OS, and HeLa cancer cells
[10,14,41]. Conversely, it was shown that knockout of REV3 re-
sulted in a pronounced growth retardation in Burkitt lymphoma cells
[42]. We found that inhibition of REV3 expression per se reduced
colony formation in lung, breast, mesothelioma, and colon tumor
cell lines. There are two possible explanations for these apparently
controversial observations on the effects of REV3 depletion in cancer
cells. First, the absence of cell growth inhibition in stable cancer cell
lines depleted of REV3 might be due to the genetic modifications
acquired during clonal selection, namely, rewiring of cell cycle check-
point pathways [43]. Thus, it would be interesting to identify if the
clones isolated in the studies mentioned acquired genetic modifi-
cations compared with their parental cell lines. Second, when in-
vestigated, it was found that inhibition of REV3 expression per se
increased DNA damage levels in cancer cells even when no effect
on cell growth/survival was mentioned [10,14,42]. Thus, it is pos-
sible that the DNA damage level necessary for DDR activation is
different in the tested cell lines, explaining the presence or absence
of growth arrest (reviewed in Al-Ejeh et al. [44]).
The second possibility is illustrated by the fact that only inhibition
of REV3 expression by high-titer transduction resulted in a reduction
of colony formation in MMR-deficient HCT116 cells, although REV3
expression was not further reduced. It was shown before that activa-
tion of the DDR is impaired in MMR-deficient HCT116 cells [45].
Thus, a higher level of cellular stress in form of additional DSBs due
to more viral integration events after high-titer transduction might
be required in HCT116 cells for the induction of a DDR resulting
in the reduced colony formation after inhibition of REV3 expression.
In addition, the p53 status influences cell fate after REV3 deple-
tion. The p53 status did not affect the accumulation of persistent
DSBs indicated by P-ATM foci after inhibition of REV3 expression
in HCT116 cells. Similarly, a recent study showed that DNA dam-
age accumulation after prolonged activation of the mitotic check-
point is also independent of the p53 status [46]. Thus, p53 does
not protect cancer cells from damage accumulation due to REV3 de-
pletion, although the subsequent cellular outcome, as discussed be-
low, is dependent on the p53 status.
Previously, accumulation of H2AX phosphorylation in U2OS hu-
man osteosarcoma cells was observed after REV3 depletion [10]. Mi-
croscopic analysis revealed that inhibition of REV3 expression in
cancer cells resulted in the accumulation of persistent DNA damage
foci, which was also observed after exposure to high-dose ionizing
radiation [31], suggesting the accumulation of irreparable DSBs.
Similarly, the accumulation of large 53BP1 foci was also observed
after the induction of mild replication stress or the genetic ablation
of the BLM helicase [47]. Interestingly, a very recent publication
showed that large 53BP1 foci mark sites of replication stress, which
is passed onto daughter cells [48], giving rise to the possibility that
the large 53BP1 foci detected after REV3 depletion mark sites of
incomplete DNA synthesis rather than DSBs due to replication
fork breakdown.
Cellular senescence limits the proliferation of damaged cells that
are at risk for neoplastic transformation (reviewed in Collado and
Serrano [34]). Our data indicate that, at least in p53-proficient can-
cer cells, senescence induction after REV3 depletion might prevent
further transformation of cancer cells by establishing an essentially
irreversible growth arrest. It is also proposed that the senescence-
associated secretory phenotype, which we observed after inhibition
of REV3 expression indicated by increased IL-6 secretion, might
stimulate the immune system to clear senescent cells (reviewed in
Collado and Serrano [34]). However, if senescent cells are not cleared
by the immune system, they remain in a “dormant” state represent-
ing a dangerous potential for tumor relapse.
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A recent study showed that nocodazole (a microtubule polymeri-
zation inhibitor) treatment of p53-deficient HCT116 cells leads to
prolonged mitosis and subsequent return of the mitotically arrested
cells to interphase without cell division resulted in aneuploidy [46], a
process known as mitotic slippage. We observed that REV3 depletion
in the p53-deficient HCT116 cell line and in combination with p53
inhibition in the A549 cell line leads to an accumulation of G2/M
arrested cells and an increase in the frequency of aneuploid cells,
which was also described in p53-deficient REV3-null MEFs [37].
On the basis of these results, we propose a model (Figure 5) in
which inhibition of REV3 expression can be tolerated in normal cells
but results in the accumulation of persistent DNA damage in cancer
cells harboring cancer-specific alterations. Accumulation of persistent
DNA damage leads in p53-proficient cancer cells to senescence,
whereas REV3 depletion in p53-deficient cells results in growth in-
hibition and a G2/M arrest. A small fraction of the p53-deficient
cancer cells can overcome the G2/M arrest, which results in mitotic
slippage and aneuploidy.
The concept of “synthetic lethality,” where defects in two path-
ways alone can be tolerated but become lethal when combined,
has been originally described in Drosophila and yeast genetic studies
[49,50]. This concept has been extended by the idea of “synthetic
sickness,” whereas the combined loss/mutation of function of two
genes does not kill cells but significantly impairs cellular fitness [51].
A recent study showed that inhibiting specific DNA repair poly-
merases induces synthetic sickness/lethality specifically in MMR-
deficient cells [52]. In analogy, we found that REV3 depletion induces
synthetic sickness/lethality in the investigated cancer cells. It will be
interesting to identify the underlying cancer-specific alteration(s),
which render the investigated cancer cell lines prone to growth inhibi-
tion due to REV3 depletion. In this context it was shown that DNA
repair and/or cell cycle checkpoint mechanisms are frequently abro-
gated in cancer cells [53], and the concentration of endogenous
DNA damage is higher in human tumoral tissue compared with the
corresponding adjacent normal tissue (reviewed in Croteau and Bohr
[54]). Therefore, differences in repair capacity or DNA damage levels
between normal and cancer cells might be the underlying cause for
the observed increased sensitivity of cancer cells to REV3 depletion.
Alternatively, replication stress due to the activation of oncogenes
might sensitize cancer cells to the inhibition of REV3 expression. A
recent study showed that overexpression of Sch9, the S. cerevisiae
homolog of the mammalian proto-oncogenes Akt and S6, increases
superoxide-dependent DNA damage, which subsequently leads to
the REV3-dependent formation of point mutations to avoid gross
chromosomal rearrangements [55]. However, we cannot exclude that
the specific genetic or epigenetic alterations underlying the observed
synthetic sickness/lethality after REV3 depletion might differ between
the tested cancer cell lines. Indeed, a recent study showed that REV3
deletion in a S. cerevisiae strain containing a particular additional chro-
mosome resulted in decreased colony formation [56].
Cancer cells can be addicted not only to oncogenes but also to
nononcogenes (reviewed in Luo et al. [57]). “Nononcogene addic-
tion” genes are also required for maintenance of the tumorigenic state
but are in contrast to oncogenes not functionally altered or mutated.
The most prominent example of a “nononcogene addiction” gene
is PARP, which is essential in BRCA-deficient breast cancer cells.
Thus, based on the results of our study, we propose that REV3
functions as a “nononcogene addiction” gene, whose depletion in-
duces synthetic sickness/lethality specifically in the investigated can-
cer cell lines. Along those lines, we are performing a genome-wide
screen to identify essential molecular pathways in cancer cells whose
inhibition will further enhance cell killing in combination with
REV3 inhibition.
It will be interesting to determine whether 1) DNA damage tol-
erance by REV3-dependent TLS, 2) REV3-dependent DNA repair,
or 3) a yet-to-be-identified function of REV3 is essential for cancer
Figure 5. Model: REV3 depletion induces persistent DNA damage specifically in cancer cells, which subsequently results in the induc-
tion of senescence in p53-proficient cancer cells and G2/M arrest in p53-deficient cancer cells. See text for details.
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cell growth. Indeed, the size of mammalian REV3 is approximately
double the size of the yeast homolog, giving rise to the possibility
that the nonconserved region of REV3 harbors a yet-to-be-identified
functional domain, necessary only in higher organisms.
Acknowledgments
The authors thank Alexandra Graf for her help in the initial experi-
ments and Bert Vogelstein for HCT116 (p53+/+) and HCT116
(p53−/−) cell lines.
References
[1] Lemontt JF (1971). Mutants of yeast defective in mutation induced by ultra-
violet light. Genetics 68, 21–33.
[2] Morrison A, Christensen RB, Alley J, Beck AK, Bernstine EG, Lemontt JF, and
Lawrence CW (1989). REV3, a Saccharomyces cerevisiae gene whose function
is required for induced mutagenesis, is predicted to encode a nonessential DNA
polymerase. J Bacteriol 171, 5659–5667.
[3] Lawrence CW, Das G, and Christensen RB (1985). REV7, a new gene concerned
with UV mutagenesis in yeast. Mol Gen Genet 200, 80–85.
[4] Waters LS, Minesinger BK, Wiltrout ME, D’Souza S, Woodruff RV, and
Walker GC (2009). Eukaryotic translesion polymerases and their roles and reg-
ulation in DNA damage tolerance. Microbiol Mol Biol Rev 73, 134–154.
[5] Bemark M, Khamlichi AA, Davies SL, and Neuberger MS (2000). Disruption
of mouse polymerase ζ (Rev3) leads to embryonic lethality and impairs blasto-
cyst development in vitro. Curr Biol 10, 1213–1216.
[6] Esposito G, Godindagger I, Klein U, Yaspo ML, Cumano A, and Rajewsky K
(2000). Disruption of the Rev3l-encoded catalytic subunit of polymerase ζ in
mice results in early embryonic lethality. Curr Biol 10, 1221–1224.
[7] Wittschieben J, Shivji MK, Lalani E, Jacobs MA, Marini F, Gearhart PJ,
Rosewell I, Stamp G, and Wood RD (2000). Disruption of the developmentally
regulated Rev3l gene causes embryonic lethality. Curr Biol 10, 1217–1220.
[8] O-Wang J, Kajiwara K, Kawamura K, Kimura M, Miyagishima H, Koseki H,
and Tagawa M (2002). An essential role for REV3 in mammalian cell survival:
absence of REV3 induces p53-independent embryonic death. Biochem Biophys
Res Commun 293, 1132–1137.
[9] Rajpal DK, Wu X, and Wang Z (2000). Alteration of ultraviolet-induced muta-
genesis in yeast through molecular modulation of the REV3 and REV7 gene ex-
pression. Mutat Res 461, 133–143.
[10] Brondello JM, Pillaire MJ, Rodriguez C, Gourraud PA, Selves J, Cazaux C, and
Piette J (2008). Novel evidences for a tumor suppressor role of Rev3, the cata-
lytic subunit of Pol ζ. Oncogene 27, 6093–6101.
[11] Wang H, Zhang SY, Wang S, Lu J, Wu W, Weng L, Chen D, Zhang Y, Lu Z,
Yang J, et al. (2009). REV3L confers chemoresistance to cisplatin in human
gliomas: the potential of its RNAi for synergistic therapy. Neuro Oncol 11,
790–802.
[12] Nojima K, Hochegger H, Saberi A, Fukushima T, Kikuchi K, Yoshimura M,
Orelli BJ, Bishop DK, Hirano S, Ohzeki M, et al. (2005). Multiple repair path-
ways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate
cells. Cancer Res 65, 11704–11711.
[13] Raschle M, Knipscheer P, Enoiu M, Angelov T, Sun J, Griffith JD, Ellenberger
TE, Scharer OD, and Walter JC (2008). Mechanism of replication-coupled
DNA interstrand crosslink repair. Cell 134, 969–980.
[14] Hicks JK, Chute CL, Paulsen MT, Ragland RL, Howlett NG, Gueranger Q,
Glover TW, and Canman CE (2010). Differential roles for DNA polymerases ɛ,
ζ, and REV1 in lesion bypass of intrastrand versus interstrand DNA cross-links.
Mol Cell Biol 30, 1217–1230.
[15] Wu F, Lin X, Okuda T, and Howell SB (2004). DNA polymerase ζ regulates
cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin
resistance. Cancer Res 64, 8029–8035.
[16] Schenten D, Kracker S, Esposito G, Franco S, Klein U, Murphy M, Alt FW,
and Rajewsky K (2009). Pol ζ ablation in B cells impairs the germinal center
reaction, class switch recombination, DNA break repair, and genome stability.
J Exp Med 206, 477–490.
[17] Gibbs PE, McGregor WG, Maher VM, Nisson P, and Lawrence CW (1998). A
human homolog of the Saccharomyces cerevisiae REV3 gene, which encodes the
catalytic subunit of DNA polymerase ζ. Proc Natl Acad Sci USA 95, 6876–6880.
[18] Diaz M, Watson NB, Turkington G, Verkoczy LK, Klinman NR, and McGregor
WG (2003). Decreased frequency and highly aberrant spectrum of ultraviolet-
induced mutations in the hprt gene of mouse fibroblasts expressing antisense
RNA to DNA polymerase ζ. Mol Cancer Res 1, 836–847.
[19] Xie K, Doles J, Hemann MT, and Walker GC (2010). Error-prone translesion
synthesis mediates acquired chemoresistance. Proc Natl Acad Sci USA 107,
20792–20797.
[20] Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T,Walker GC, and HemannMT
(2010). Suppression of Rev3, the catalytic subunit of Pol{ζ}, sensitizes drug-
resistant lung tumors to chemotherapy. Proc Natl Acad Sci USA 107, 20786–20791.
[21] Wittschieben JP, Reshmi SC, Gollin SM, and Wood RD (2006). Loss of DNA
polymerase ζ causes chromosomal instability in mammalian cells. Cancer Res 66,
134–142.
[22] Van Sloun PP, Varlet I, Sonneveld E, Boei JJ, Romeijn RJ, Eeken JC, and
De Wind N (2002). Involvement of mouse Rev3 in tolerance of endogenous
and exogenous DNA damage. Mol Cell Biol 22, 2159–2169.
[23] Sonoda E, Okada T, Zhao GY, Tateishi S, Araki K, Yamaizumi M, Yagi T,
Verkaik NS, van Gent DC, Takata M, et al. (2003). Multiple roles of Rev3,
the catalytic subunit of pol ζ in maintaining genome stability in vertebrates.
EMBO J 22, 3188–3197.
[24] d’Adda di Fagagna F (2008). Living on a break: cellular senescence as a DNA-
damage response. Nat Rev Cancer 8, 512–522.
[25] Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, and Felley-Bosco E
(2009). Functional inactivation of NF2/merlin in human mesothelioma. Lung
Cancer 64, 140–147.
[26] Reed SE, Staley EM, Mayginnes JP, Pintel DJ, and Tullis GE (2006). Trans-
fection of mammalian cells using linear polyethylenimine is a simple and effec-
tive means of producing recombinant adeno-associated virus vectors. J Virol
Methods 138, 85–98.
[27] Salmon P and Trono D (2007). Production and titration of lentiviral vectors.
Curr Protoc Hum Genet Chapter 12, Unit 12 10.
[28] Marti TM,Hefner E, Feeney L, Natale V, andCleaver JE (2006).H2AX phosphor-
ylation within the G1 phase after UV irradiation depends on nucleotide excision re-
pair and not DNA double-strand breaks. Proc Natl Acad Sci USA 103, 9891–9896.
[29] Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE,
Linskens M, Rubelj I, Pereira-Smith O, et al. (1995). A biomarker that iden-
tifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad
Sci USA 92, 9363–9367.
[30] Hopkins-Donaldson S, Ziegler A, Kurtz S, Bigosch C, Kandioler D, Ludwig C,
Zangemeister-Wittke U, and Stahel R (2003). Silencing of death receptor and
caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA
methylation. Cell Death Differ 10, 356–364.
[31] Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund
A, Campeau E, Davalos AR, and Campisi J (2009). Persistent DNA damage
signalling triggers senescence-associated inflammatory cytokine secretion. Nat
Cell Biol 11, 973–979.
[32] Yamauchi M, Oka Y, Yamamoto M, Niimura K, Uchida M, Kodama S,
Watanabe M, Sekine I, Yamashita S, and Suzuki K (2008). Growth of persis-
tent foci of DNA damage checkpoint factors is essential for amplification of G1
checkpoint signaling. DNA Repair 7, 405–417.
[33] Quinn CM and Wright NA (1990). The clinical-assessment of proliferation and
growth in human tumors—evaluation of methods and applications as prognos-
tic variables. J Pathol 160, 93–102.
[34] Collado M and Serrano M (2010). Senescence in tumours: evidence from mice
and humans. Nat Rev Cancer 10, 51–57.
[35] Di Leonardo A, Linke SP, Clarkin K, and Wahl GM (1994). DNA damage
triggers a prolonged p53-dependent G1 arrest and long-term induction of
Cip1 in normal human fibroblasts. Genes Dev 8, 2540–2551.
[36] Li Z, Zhang H, McManus TP, McCormick JJ, Lawrence CW, and Maher VM
(2002). hREV3 is essential for error-prone translesion synthesis past UV or
benzo[a]pyrene diol epoxide–induced DNA lesions in human fibroblasts. Mutat
Res 510, 71–80.
[37] Zander L and Bemark M (2004). Immortalized mouse cell lines that lack a func-
tional Rev3 gene are hypersensitive to UV irradiation and cisplatin treatment.
DNA Repair 3, 743–752.
[38] Hayflick L (1965). The limited in vitro lifetime of human diploid cell strains.
Exp Cell Res 37, 614–636.
[39] Tu Y and Kim JS (2010). Selective gene transfer to hepatocellular carcinoma
using homing peptide-grafted cationic liposomes. J Microbiol Biotechnol 20,
821–827.
Neoplasia Vol. 13, No. 10, 2011 REV3 Depletion Per Se Reduces Cancer Cell Growth Knobel et al. 969
[40] Hillegass JM, Shukla A, MacPherson MB, Bond JP, Steele C, and Mossman BT
(2010). Utilization of gene profiling and proteomics to determine mineral path-
ogenicity in a human mesothelial cell line (LP9/TERT-1). J Toxicol Environ
Health A 73, 423–436.
[41] Lin X and Howell SB (2006). DNA mismatch repair and p53 function are major
determinants of the rate of development of cisplatin resistance. Mol Cancer Ther
5, 1239–1247.
[42] Gueranger Q, Stary A, Aoufouchi S, Faili A, Sarasin A, Reynaud CA, and Weill
JC (2008). Role of DNA polymerases ɛ, ι and ζ in UV resistance and UV-induced
mutagenesis in a human cell line. DNA Repair 7, 1551–1562.
[43] Reinhardt HC, Aslanian AS, Lees JA, and Yaffe MB (2007). p53-deficient cells
rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/
MK2 pathway for survival after DNA damage. Cancer Cell 11, 175–189.
[44] Al-Ejeh F, Kumar R, Wiegmans A, Lakhani SR, Brown MP, and Khanna KK
(2010). Harnessing the complexity of DNA-damage response pathways to im-
prove cancer treatment outcomes. Oncogene 29, 6085–6098.
[45] Brown KD, Rathi A, Kamath R, Beardsley DI, Zhan Q, Mannino JL, and
Baskaran R (2003). The mismatch repair system is required for S-phase check-
point activation. Nat Genet 33, 80–84.
[46] Dalton WB, Yu B, and Yang VW (2010). p53 suppresses structural chromo-
some instability after mitotic arrest in human cells. Oncogene 29, 1929–1940.
[47] Lukas C, Savic V, Bekker-Jensen S, Doil C, Neumann B, Pedersen RS, Grofte
M, Chan KL, Hickson ID, Bartek J, et al. (2011). 53BP1 nuclear bodies form
around DNA lesions generated by mitotic transmission of chromosomes under
replication stress. Nat Cell Biol 13, 243–253.
[48] Harrigan JA, Belotserkovskaya R, Coates J, Dimitrova DS, Polo SE, Bradshaw CR,
Fraser P, and Jackson SP (2011). Replication stress induces 53BP1-containing
OPT domains in G1 cells. J Cell Biol 193, 97–108.
[49] Dobzhansky T (1946). Genetics of natural populations. XIII. Recombination and
variability in populations of Drosophila pseudoobscura. Genetics 31, 269–290.
[50] Hartman JLT, Garvik B, and Hartwell L (2001). Principles for the buffering of
genetic variation. Science 291, 1001–1004.
[51] Kaelin WG Jr (2005). The concept of synthetic lethality in the context of anti-
cancer therapy. Nat Rev Cancer 5, 689–698.
[52] Martin SA, McCabe N, Mullarkey M, Cummins R, Burgess DJ, Nakabeppu Y,
Oka S, Kay E, Lord CJ, and Ashworth A (2010). DNA polymerases as potential
therapeutic targets for cancers deficient in the DNA mismatch repair proteins
MSH2 or MLH1. Cancer Cell 17, 235–248.
[53] Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested
M, Nesland JM, Lukas C, et al. (2005). DNA damage response as a candidate
anti-cancer barrier in early human tumorigenesis. Nature 434, 864–870.
[54] Croteau DL and Bohr VA (1997). Repair of oxidative damage to nuclear and
mitochondrial DNA in mammalian cells. J Biol Chem 272, 25409–25412.
[55] Madia F, Wei M, Yuan V, Hu J, Gattazzo C, Pham P, Goodman MF, and
Longo VD (2009). Oncogene homologue Sch9 promotes age-dependent muta-
tions by a superoxide and Rev1/Pol ζ–dependent mechanism. J Cell Biol 186,
509–523.
[56] Sheltzer JM, Blank HM, Pfau SJ, Tange Y, George BM, Humpton TJ, Brito IL,
Hiraoka Y, Niwa O, and Amon A (2011). Aneuploidy drives genomic instabil-
ity in yeast. Science 333, 1026–1030.
[57] Luo J, Solimini NL, and Elledge SJ (2009). Principles of cancer therapy: onco-
gene and non-oncogene addiction. Cell 136, 823–837.
970 REV3 Depletion Per Se Reduces Cancer Cell Growth Knobel et al. Neoplasia Vol. 13, No. 10, 2011
Supplemental Materials and Methods
Cell Lines
The human MPM cell line ZL55 and the primary cell culture
SDM104 were generated in our laboratory [25,30]. The rat MPM
cell line IL45 was generated elsewhere (Craighead et al., Am J Pathol.
1987;129:448–462). The breast cancer cell lines MDA-MB-231 and
MCF-7, the adenocarcinoma Calu-3, the squamous non–small cell
lung cancer cell line A549 and the HEK 293T were purchased from
American Type Culture Corporation (Manassas, VA). The AD293 cell
line, a HEK 293 derivative with improved cell adherence, was pur-
chased from Stratagene (La Jolla, CA). The colorectal carcinoma cell
lines HCT116 40.16 (p53+/+) and HCT116 379.2 (p53−/−) were
kindly provided by Dr Bert Vogelstein ( Johns Hopkins University,
Baltimore, MD).
Reagents
When indicated, 20 μM cisplatin (Ebewe Pharma, Cham,
Switzerland) was added for 24 hours.
To clone the short hairpin constructs into the plasmid pSuperior.puro,
the following DNA oligonucleotides were ordered from Microsynth:
shREV3-4:
5′-GATCCCCCAAAGATGCTGCTACATTATTCAAGA-
GATAATGTAGCAGCATCTTTGTTTTTA-3′
5′-AGCTTAAAAACAAAGATGCTGCTACATTATCTCTT-
GAATAATGTAGCAGCATCTTTGGGG-3′
shREV3-5:
5′-GATCCCCGATATTCCATCTGTTACAATTCAAGA-
GATTGTAACAGATGGAATATCTTTTTA-3′
5′-AGCTTAAAAAGATATTCCATCTGTTACAATCTCTT-
GAATTGTAACAGATGGAATATCGGG-3′
shREV3-6:
5′-GATCCCCTAGTCAGACTTTTCAGCCTTTCAAGA-
GAAGGCTGAAAAGTCTGACTATTTTTA-3′
5′-AGCTTAAAAATAGTCAGACTTTTCAGCCTTCTCTT-
GAAAGGCTGAAAAGTCTGACTAGGG-3′
shSCR:
5′-GATCCCCATTCTAGGTGAAAGCTAATTTCAAGA-
GATAAGATCCACTTTCGATTATTTTTA-3′
5′-AGCTTAAAAATAATCGAAAGTGGATCTTATCTCTT-
GAAATTAGCTTTCACCTAGAATGGG-3′
shP53:
5′-GATCCCCGACTCCAGTGGTAATCTACTTCAAGA-
GAGTAGATTACCACTGGAGTCTTTTTA-3′
5′-AGCTTAAAAAGACTCCAGTGGTAATCTACTCT-
CTTGAAGTAGATTACCACTGGAGTCGGG-3′
To quantitatively measure the expression of REV3 mRNA by
real-time PCR, the following DNA oligonucleotides were ordered
from Microsynth:
REV3:
Forward 5′-TGAGTTCAAATTTGGCTGTACCT-3′
REV3:
Reverse 5′-TCTAGTCTTCAAAATTTCTTCAAGCA-3′
Histone H3:
Forward 5′-TAAAGCACCCAGGAAACAACTGGC-3′
Reverse 5′-ACCAGGCCTGTAACGATGAGGTTT-3′
P53:
Forward 5′-GCTTTGAGGTTCGTGTTTGTGCCT-3′
Reverse 5′-GCCCACGGATCTTAAGGGTGAAAT-3′
For Western analysis, the following primary antibodies were diluted
at 1:1000: PARP (no. 9542; Cell Signaling, Beverly, MA), P-Chk2
(no. AF1626; R&D Systems), p53 (no. 9282; Cell Signaling), p21
(no. sc-756; Santa Cruz, Santa Cruz, CA), cyclin E (no. sc-247; Santa
Cruz), and MAD2B/Rev7 (no. 612266; BD Biosciences). The pri-
mary antibody β-actin (no. 691001; MP Biomedicals, Solon, OH)
was incubated 1:10,000 for 1 hour at room temperature. The secondary
polyclonal antibodies coupled to horseradish peroxidase were diluted
at 1:10,000.
For immunofluorescence microscopy, the following primary anti-
bodies were used: P-ATM 1:1000 (no. sc-4526; Cell Signaling),
γH2AX 1:1000 (no. 05-636; Upstate Biotechnology, Lake Placid,
NY), 53BP1 1:500 (no. 4937; Cell Signaling), and BrdU 1:1000
(no. 555627; BD Biosciences).
Vector Production and Transduction
Short hairpin REV3-4 and scrambled (shSCR) oligos were ligated
into pSuperior.puro as described by the manufacturer (OligoEngine,
Seattle, WA). The shRNA and H1 promoter fragments were subse-
quently ligated into the constitutive expressing lentiviral vector
pLVTHM (Addgene, Cambridge, MA). Replication-deficient lentiviral
particles were produced and titrated as described previously [26,27].
Cells were seeded in six-well plates (colony formation, immuno-
fluorescence, and SA-β-galactosidase assay: 500 cells/well [SDM104:
1000 cells/well]; FACS andWestern analysis: 2500 cells/well [SDM104:
5000 cells/well]; real-time PCR and ELISA: 5000 cells/well) in 2 ml
of medium. After 6 hours, the medium was removed, and lentivirus
suspension was added for 30 minutes in 300 μl (immunofluorescence,
FACS, and real-time PCR: MOI = 100; Western analysis and colony
formation: MOI = 170). All transductions of HCT116 and the
corresponding control AD293 cells were performed with an MOI of
800 and were incubated for 1 hour. Subsequently, medium was added
to final volume of 1.5 ml. For mock treatment, 0.5-μm filtered condi-
tionedmedium from a HEK 293T culture was added. After 7 days, cells
were further processed for distinct experiment as described below except
for colony formation, which were incubated longer as described below.
Quantitative Real-time PCR
Real-time PCR cycle conditions were as follows: one cycle of 95°C
for 10 minutes, 40 cycles of 95°C for 15 seconds and 60°C for 1 min-
ute, and one cycle of 95°C for 15 seconds and from 60°C slowly
elevating to 95°C for several minutes for dissociation curve analysis.
Histone H3 expression was used to standardize the total amount of
complementary DNA, and the specificity of the PCR was confirmed
by analysis of the melting curve.
Immunofluorescence Microscopy
Immunofluorescence microscopy was performed essentially as de-
scribed before [28]. In detail, for BrdU staining, cells were incubated
with 10 μM BrdU for 1 hour. Fixation and permeabilization were
done with 100% methanol at −20°C and acetone-methanol (50:50)
at −20°C for 20 minutes at room temperature, respectively. Cells
were washed 2 × 5 minutes with PBS. For BrdU staining, cells were
denatured with 2 M HCl for 30 minutes at room temperature and
subsequently washed 3 × 5 minutes with PBS. PBS containing 1%
fetal bovine serum and 10% bovine serum albumin was used as block-
ing solution for 1 hour at room temperature. First, antibodies were
diluted in blocking solution and incubated at 4°C overnight. The
following antibodies were used: P-ATM 1:1000 (no. sc-4526; Cell
Signaling), γH2AX 1:1000 (no. 05-636; Upstate), 53BP1 1:500
(no. 4937; Cell Signaling), and BrdU 1:1000 (no. 555627; BD Biosci-
ences). Cells were washed 2 × 5 minutes in PBS. Secondary anti-
bodies were diluted at 1:10,000 in blocking solution and incubated
at 37°C for 1 hour. Cells were washed 2 × 5 minutes with PBS and
mounted with ProLong Gold Antifade reagent with 4′,6-diamidino-
2-phenylindole (no. P36931; Invitrogen). Images were acquired with
an inverse wide-field fluorescence microscope (DM IRBE; Leica,
Bensheim, Germany) equipped with a black and white camera
(ORKA-ER; Hamamatsu, Hamamatsu, Japan). Image processing with
Photoshop (Adobe Systems) was applied to whole images only. Images
used for comparison between different transductions were acquired
with the same instrument settings and exposure time and were pro-
cessed equally.
Flow Cytometry
Cell cycle distributionwas assessed by using a FACSCalibur (FACScan,
488-nm excitation laser; BD Biosciences) and WinMDI software.
Western Analysis
Cells were lysed for 30 minutes on ice in 1× RIPA buffer (Upstate)
containing 2 × HALT protease and phosphatase inhibitor cocktail
(Thermo Scientific, Rockford, IL). Cell extracts were denatured at
95°C for 5 minutes and homogenized by successive passing through
a 30-gauge syringe needle, and protein concentrations were deter-
mined using bicinchoninic acid protein assay (Pierce, Rockford, IL).
Figure W1. Efficient inhibition of REV3 expression after transduction with lentiviral-based particles. Cells were mock treated or trans-
duced with lentiviral-based particles containing either shSCR or shREV3 and/or lentiviral-based particles containing shP53. REV3 (A and
B) and P53 (C) expression were analyzed by quantitative real-time PCR 7 days after transduction. The averages of at least three inde-
pendent experiments are given for A549, IL45, p53-proficient HCT116, p53-deficient HCT116, SDM104, and AD293 cells, whereas rep-
resentative experiments are shown for Calu-3, MDA-MB-231, MCF-7, ZL55, and LP9-hTERT cells. Rev3 expression levels were
normalized to histone H3 expression levels. All Rev3 and p53 expression levels are reported as percentage compared with mock-treated
A549 (A and C) or p53-proficient HCT116 (B) cells, which was set as 100%. Shown are means ± SD.
Figure W2. REV3 silencing specifically reduces colony formation of
cancer cells. Cancer cells A549, IL45, MDA-MB-231, p53-proficient
HCT116, p53-deficient HCT116, and normal cells AD293 were either
mock treated or transduced with lentiviral-based particles contain-
ing shSCR or shREV3. Crystal violet staining was performed once
colonies were visible by eye. (A) MOI = 170. (B) MOI = 800. Experi-
ments were made in duplicate wells. See also related Figure 1.
Figure W3. Reduced colony formation after REV3 silencing is not
due to an siRNA off-target effect. IL45 mesothelioma cancer cells
and AD293 normal cells were either mock treated or transfected
with three different plasmids containing shRNA constructs target-
ing Rev3. Colonies were stained with crystal violet and counted
after 2 weeks. Experiment was made in duplicate wells.
Figure W4. REV3 depletion induces persistent DNA damage in MCF-7 breast cancer cells. Cells were mock treated or transduced with
lentiviral-based particles containing either shSCR or shREV3 and analyzed after 1 week. Cells were stained for γH2AX or BrdU and 53BP1
and quantified by immunofluorescence microscopy. Cells containing more than two 53BP1 foci per cell were considered as positive for
53BP1. At least two independent experiments were analyzed. *P < .05. **P < .01. Shown are means ± SD.
Figure W5. REV3 depletion induces DDR pathway specifically in
cancer cells. Cells were mock treated or transduced with lentiviral-
based particles containing either shSCR or shREV3. After 1 week,
whole-cell lysates were analyzed by Western analysis.
Figure W6. REV3 silencing induces senescence in p53-proficient cancer cells. Cancer cells A549, IL45, MDA-MB-231, p53-proficient
HCT116, and p53-deficient HCT116 and normal cells AD293 were mock treated or transduced with either lentiviral-based particles con-
taining shSCR or shREV3. Crystal violet assay (upper lines) or SA-β-galactosidase assay (bottom lines) was performed after 7 days.
